comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists An Observational Study of of vs Glucagon-Like Peptide-1 Receptor Frontiers | Glucagon-like peptide-1 receptor
Description
A crucial area of our practice involves therapies based on GLP-1 (glucagon-like peptide-1), a naturally occurring hormone produced in the intestines
Despite variations in data sources, adjustment techniques, risk estimates, and comparator drugs, these findings collectively suggest that GLP-1RAs are not associated with an altered risk of depression
Sharif S, Van der Graaf Y, Cramer MJ, Kapelle LJ, de Borst GJ, Visseren FLJ, Westerink J, group Ss
Citation: Rehan Haider, Shabana N
Instead, compounded alternatives may be prescribed when clinically appropriate and legally permissible
